Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Accumulated Depreciation (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Accumulated Depreciation data on record, last reported at $298.3 million in Q3 2025.

  • For Q3 2025, Accumulated Depreciation changed N/A year-over-year to $298.3 million; the TTM value through Sep 2025 reached $298.3 million, changed N/A, while the annual FY2024 figure was $271.6 million, 10.72% up from the prior year.
  • Accumulated Depreciation reached $298.3 million in Q3 2025 per AMPH's latest filing, up from $271.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $298.3 million in Q3 2025 and bottomed at $194.6 million in Q3 2021.
  • Average Accumulated Depreciation over 5 years is $231.5 million, with a median of $226.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation: increased 8.4% in 2021, then increased 11.48% in 2023.
  • A 5-year view of Accumulated Depreciation shows it stood at $199.6 million in 2021, then increased by 10.22% to $220.0 million in 2022, then rose by 11.48% to $245.3 million in 2023, then rose by 10.72% to $271.6 million in 2024, then grew by 9.83% to $298.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $298.3 million in Q3 2025, $271.6 million in Q4 2024, and $245.3 million in Q4 2023.